Key result
Canagliflozin demonstrates consistent cardiovascular and renal benefits in patients with type 2 diabetes.
Answers are grounded in this paper and cite their sources.
SGLT2 inhibitors have risen to prominence in recent years as Type 2 diabetes mellitus medications with favorable effects on cardiovascular (CV) and renal outcomes. Canagliflozin is a US FDA-approved SGLT2 inhibitor that has demonstrated CV and renal outcome benefits in large scale placebo-controlled randomized trials of patients with Type 2 diabetes mellitus and elevated CV risk. Canagliflozin use may also be associated with serious and nonserious adverse effects requiring ongoing monitoring in patients initiated on this medication. This paper provides a detailed overview of canagliflozin including its pharmacologic profile, clinical efficacy and safety data, with discussion of both clinical trial results, as well as real-world evidence.
No takes yet. Share an insight, caveat, or question.
Sarraju et al. (2020) conducted a review in Type 2 diabetes mellitus and elevated cardiovascular risk. Canagliflozin vs. Placebo was evaluated on Cardiovascular and renal outcomes. Canagliflozin has demonstrated cardiovascular and renal outcome benefits in placebo-controlled trials of Type 2 diabetes patients, though no specific quantitative data are reported in this review.
Synapse has enriched 10 related papers. Consider them for comparative context: